Literature DB >> 29541365

In Search of the Optimal Macrocyclization Site for Neurotensin.

Marc Sousbie1, Élie Besserer-Offroy1, Rebecca L Brouillette1, Jean-Michel Longpré1, Richard Leduc1, Philippe Sarret1, Éric Marsault1.   

Abstract

Neurotensin exerts potent analgesic effects following activation of its cognate GPCRs. In this study, we describe a systematic exploration, using structure-based design, of conformationally constraining neurotensin (8-13) with the help of macrocyclization and the resulting impacts on binding affinity, signaling, and proteolytic stability. This exploratory study led to a macrocyclic scaffold with submicromolar binding affinity, agonist activity, and greatly improved plasma stability.

Entities:  

Year:  2018        PMID: 29541365      PMCID: PMC5846049          DOI: 10.1021/acsmedchemlett.7b00500

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  39 in total

1.  Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.

Authors:  Jürgen Einsiedel; Harald Hübner; Maud Hervet; Steffen Härterich; Susanne Koschatzky; Peter Gmeiner
Journal:  Bioorg Med Chem Lett       Date:  2008-02-02       Impact factor: 2.823

Review 2.  The exploration of macrocycles for drug discovery--an underexploited structural class.

Authors:  Edward M Driggers; Stephen P Hale; Jinbo Lee; Nicholas K Terrett
Journal:  Nat Rev Drug Discov       Date:  2008-07       Impact factor: 84.694

3.  A C-terminal cyclic 8-13 neurotensin fragment analog appears less exposed to neprilysin when it crosses the blood-brain barrier than the cerebrospinal fluid-brain barrier in mice.

Authors:  F M Van Kemmel; I Dubuc; E Bourdel; J A Fehrentz; J Martinez; J Costentin
Journal:  Neurosci Lett       Date:  1996-10-11       Impact factor: 3.046

Review 4.  Neurotensin and neurotensin receptors.

Authors:  J P Vincent; J Mazella; P Kitabgi
Journal:  Trends Pharmacol Sci       Date:  1999-07       Impact factor: 14.819

5.  NTS1 and NTS2 mediate analgesia following neurotensin analog treatment in a mouse model for visceral pain.

Authors:  Kristin E Smith; Mona Boules; Katrina Williams; Elliott Richelson
Journal:  Behav Brain Res       Date:  2012-04-05       Impact factor: 3.332

6.  Functional activity of new C-terminal cyclic-neurotensin fragment analogs.

Authors:  H C Akunne; S Darling; K Zoski; A M Sefler; J X He; T K Sawyer; T A Pugsley; W L Cody
Journal:  Neuropeptides       Date:  1996-06       Impact factor: 3.286

7.  Neurotensin analogs [D-TYR11] and [D-PHE11]neurotensin resist degradation by brain peptidases in vitro and in vivo.

Authors:  F Checler; J P Vincent; P Kitabgi
Journal:  J Pharmacol Exp Ther       Date:  1983-12       Impact factor: 4.030

8.  Spinal NTS2 receptor activation reverses signs of neuropathic pain.

Authors:  Pascal Tétreault; Nicolas Beaudet; Amélie Perron; Karine Belleville; Adeline René; Florine Cavelier; Jean Martinez; Thomas Stroh; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Philippe Sarret
Journal:  FASEB J       Date:  2013-06-11       Impact factor: 5.191

9.  Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model.

Authors:  Geneviève Roussy; Marc-André Dansereau; Louis Doré-Savard; Karine Belleville; Nicolas Beaudet; Elliott Richelson; Philippe Sarret
Journal:  J Neurochem       Date:  2007-12-25       Impact factor: 5.372

10.  Increased Conformational Flexibility of a Macrocycle-Receptor Complex Contributes to Reduced Dissociation Rates.

Authors:  Adrian Glas; Eike-Christian Wamhoff; Dennis M Krüger; Christoph Rademacher; Tom N Grossmann
Journal:  Chemistry       Date:  2017-08-30       Impact factor: 5.236

View more
  1 in total

Review 1.  Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles.

Authors:  Dianqing Sun
Journal:  Molecules       Date:  2022-02-02       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.